Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 5
Artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria
Authors Ehrhardt S, Meyer CG
Published 6 October 2009 Volume 2009:5 Pages 805—815
DOI https://doi.org/10.2147/TCRM.S5375
Review by Single anonymous peer review
Peer reviewer comments 3
Stephan Ehrhardt, Christian G Meyer
Bernhard Nocht Institute for Tropical Medicine, Tropical Medicine Section, Hamburg, Germany
Abstract: The World Health Organization strongly recommends artemisinin-based combination therapy (ACT) regimens for the treatment of uncomplicated Plasmodium falciparum malaria cases in endemic areas. Among the combinations of compounds that are available at present, excellent results have been obtained for the artemisinin derivative artemether, in a combination galenic preparation with lumefantrine (artemether–lumefantrine, AL). Here, the pharmacological properties and the therapeutic options of both substances are briefly reviewed and a cursory overview is given on recent trials that have compared the therapeutic effects of AL in the standard 6-dose regimen with other antimalarials and combinations. In order to ensure the most achievable and reliable adherence and compliance of children in the treatment of malaria, a dispersible formulation of AL is now attainable. Recent reports on the emergence of resistance to ACT regimens in Asia, however, are alarming.
Keywords: artemether, lumefantrine, malaria, Plasmodium falciparum, dispersible formulation, treatment, therapy
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.